【摘要】：目的:探究荷丹片對冠心病合并2型糖尿病患者血脂、炎癥因子及氧化應激水平的影響及安全性。方法:收集2013年7月-2015年11月我院收治的冠心病合并2型糖尿病患者118例,按隨機數字表法分為觀察組(63例)和對照組(55例)。對照組患者給予控制血糖、調節(jié)血脂、擴張血管、抗凝等常規(guī)治療;觀察組患者在對照組基礎上餐前口服荷丹片1.46 g,tid。兩組患者均連續(xù)治療6個月。比較兩組患者治療前后血脂[總膽固醇(TC)、三酰甘油(TG)、低密度脂蛋白膽固醇(LDL-C)、高密度脂蛋白膽固醇(HDL-C)]、血清炎癥因子[腫瘤壞死因子α(TNF-α)、白細胞介素10(IL-10)、IL-6、超敏C反應蛋白(hs-CRP)]、血清氧化應激指標[丙二醛(MDA)、超氧化物歧化酶(SOD)、一氧化氮(NO)]水平及不良反應發(fā)生情況。結果:治療前,兩組患者血脂、炎癥因子及氧化應激指標水平比較,差異均無統計學意義(P0.05);治療后,兩組患者TC、TG、LDL-C、TNF-α、IL-6、hs-CRP、MDA水平顯著降低,IL-10、SOD、NO水平顯著升高,且觀察組上述指標均顯著優(yōu)于對照組,差異均有統計學意義(P0.05)。兩組患者不良反應發(fā)生率比較,差異無統計學意義(P0.05)。結論:荷丹片能有效改善冠心病合并2型糖尿病患者血脂及血清炎癥因子水平,減輕炎性損傷,降低氧自由基水平,增強機體抗氧化能力,減輕氧化應激損傷,且安全性較高。
[Abstract]:Aim: to investigate the effect and safety of Hedan tablets on serum lipids, inflammatory factors and oxidative stress in patients with coronary heart disease (CHD) complicated with type 2 diabetes. Methods: 118 cases of coronary heart disease complicated with type 2 diabetes were collected from July 2013 to November 2015 in our hospital. According to the method of random number table, they were divided into observation group (63 cases) and control group (55 cases). The patients in the control group were given routine treatment such as controlling blood glucose, regulating blood lipids, dilating blood vessels and anticoagulant, while the patients in the observation group were given 1.46 g Hedan tablet before meal on the basis of the control group. The patients in both groups were treated continuously for 6 months. Serum lipids [total cholesterol (TC), triacylglycerol (TG), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C)] were compared between the two groups before and after treatment. Serum inflammatory factor [tumor necrosis factor 偽 (TNF- 偽), interleukin 10 (IL-10), IL-6, hypersensitive C-reactive protein (hs-CRP)], serum oxidative stress index [malondialdehyde (MDA), superoxide dismutase (SOD),] The level of nitric oxide (NO) and the occurrence of adverse reactions. Results: before treatment, the levels of blood lipids, inflammatory factors and oxidative stress were not significantly different between the two groups (P0.05). After treatment, the levels of TC,TG,LDL-C,TNF- 偽, IL-6,hs-CRP,MDA and IL-10,SOD,NO in the two groups were significantly decreased, and the above indexes in the observation group were significantly better than those in the control group. The difference was statistically significant (P0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P0.05). Conclusion: Hedan tablet can effectively improve blood lipids and serum inflammatory factors in patients with coronary heart disease and type 2 diabetes mellitus, reduce inflammatory injury, reduce oxygen free radicals, enhance the ability of body anti-oxidation, reduce oxidative stress injury, and have higher safety.
【作者單位】： 漯河市中心醫(yī)院藥學部;漯河市中心醫(yī)院內分泌代謝科;
【分類號】：R541.4;R587.1

【相似文獻】

相關期刊論文 前2條

1 陳亞麗;;荷丹片聯合阿托伐他汀對頸動脈粥樣硬化患者炎性細胞因子的干預影響[J];中西醫(yī)結合心腦血管病雜志;2012年07期

2 楊錫珍;楊國亮;苗少輝;徐洋;尹冬梅;;超聲評價荷丹片聯合阿托伐他汀治療頸動脈粥樣硬化的療效[J];河北醫(yī)藥;2013年18期

，

本文編號：2328539